The EMA has published a new Q&A Document on the Clinical Trials Information System (CTIS) and Clinical Trials Regulation (CTR), which covers various aspects including Safety Reporting.
The EMA has sent a letter to EU QPPVs regarding the international transfer of personal data in ICSRs originating from EudraVigilance, highlighting that some MAHs violated European Data Privacy requirements when submitting ICSRs to third countries.
The FDA has published a new draft guidance entitled “Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development”.
The FDA has announced a series of public meetings over the next few months. The topics include the use of ICH E2B(R3), the post approval assessment of cell and gene therapy products, and Immune Globulin (IG) hypersensitivity reactions.
Both the EMA and the MHRA have started a review of medicines containing pseudoephedrine over the risk of specific ischaemic events (PRES and RCVS).
You’re already leaving ? Would you like to see a sample report ? Enter your email address below to have the PDF report sent to you immediately
Would you like to see a sample report ? Enter your email address below to have the PDF report sent to you immediately
You’re already leaving ? Would you like to see a sample report ? Enter your email address below to have the PDF report sent to you immediately
Would you like to see a sample report ? Enter your email address below to have the PDF report sent to you immediately